AGOURA HILLS, Calif.,
June 19, 2013 /PRNewswire/
-- Biozoom (OTC QB: BIZM), developer of the world's first
portable, handheld device for real-time spectroscopic analysis of
biomarkers in the human body, is willing to discuss intellectual
property (IP) licensing and other models of partnership. "We
believe in innovation and would like to help foster it in companies
that share our values," said Hardy
Hoheisel, Biozoom's CEO.
Developing new applications for handheld and nano-scale
spectroscopy will remain the company's core business. Licensing
Biozoom's intellectual property to other innovative companies would
be an additional revenue stream for Biozoom.
The patent-supported technology underlying the Biozoom scanner
has been tested in clinical trials at respected institutions in
Germany. Biozoom's portfolio of
patented and patent-pending advancements span areas as diverse as
optics, temperature drift, nanofiltration, data base management,
spectroscopy and more.
Biozoom's optical work alone has a myriad of potential
applications outside of the company's strategic core health and
wellness applications. For example, Biozoom's miniaturization of
the Fabry-Perot Filtration could also be widely useful to improve
future businesses. Where digital cameras use three filters to
capture images, Biozoom's nanofiltration allows 256 filters to
capture fine detail in a 1 mm by 1 mm area. Miniaturization allows
for this technology to be embedded into systems and products where
imaging data might prove useful but is otherwise unavailable. "The
potential of this technology is greater than one company can
exploit fully," said Biozoom's Chief Technology Officer, Dr.
Wolfgang Kocher. "We hope that our
intellectual property assets can be licensed to and utilized by
other companies for a myriad of commercial uses outside of the
health and wellness industries."
About Biozoom
Biozoom is an innovative technology development company,
specializing in the commercialization of our advances in mobile
spectroscopy. Our intellectual property portfolio and ongoing
research are positioned to apply Biozoom's technology breakthroughs
to a wide range of markets. Our first consumer product, the Biozoom
scanner, gives people the feedback they need to manage their
health, wellness and fitness on demand. Tested in leading
health institutions, our scanner is the first of its
kind—a handheld, transdermal device for measuring biomarkers,
including antioxidant levels, at the click of a button. Scan
results—and customized wellness coaching based on those
biomarkers—are sent instantly to a smartphone or online
account. The scanner will enable leaders in the health and
wellness industry to create new levels of customer loyalty and
revenues as a result. For more information, visit
www.biozoom.net.
Disclaimer
This press release contains "forward-looking statements".
Statements in this press release which are not purely historical
are forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future,
and specifically references to future potential purchase orders and
re-orders from consumers and distributors. The reader can identify
these forward-looking statements by forward-looking words such as
"may," "will," "expect," "potential," "anticipate," "forecast,"
"believe," "estimate," "project," "plan," "continue" or similar
words. The reader should read statements that contain these words
carefully because they discuss future expectations, contain
projections of future results of operations or of financial
condition, or state other forward-looking information.
Forward-looking statements include, but are not limited to,
statements regarding potential products, customers, revenues,
expansion efforts, and future plans and objectives of Biozoom, Inc.
("Biozoom"). The risk factors listed in our disclosure documents
and the cautionary language therein provide examples of risks,
uncertainties and events that may cause actual results to differ
materially from the expectations and projections described by
Biozoom in its forward-looking statements. Actual results relating
to, among other things, product launch, sales, customer acceptance
and market share could differ materially from those currently
anticipated in such statements. Factors affecting forward-looking
statements include: consumer preferences, competition from more
established brands, ability to develop market share; changes in the
operating costs; changes in economic conditions, foreign exchange
and other financial markets; changes of the interest rates on
borrowings; changes in the investments levels; litigation;
legislation; environmental, judicial, regulatory, political and
competitive developments in areas in which Biozoom operates;
technological, mechanical and operational difficulties encountered
in connection with Biozoom's development activities; and labor
relation matters and costs. The reader should refer to the risk
disclosures set out in the periodic reports and other disclosure
documents filed by Biozoom from time to time with the Securities
and Exchange Commission and other regulatory authorities.
SOURCE Biozoom